24 February 2017 ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016
20 February 2017 ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA
30 January 2017 ORYZON to outline development of Lysine Specific Demethylase Inhibitors for Oncological and Neurodegenerative Diseases at Keystone Symposia on Epigenetics and Human Disease
25 January 2017 ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria
9 January 2017 ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC)
21 December 2016 ORYZON Receives a New 0.8 M USD Public Grant to Explore New Indications for Epigenetic Inhibitors